Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.
de Bruin RC, Stam AG, Vangone A, van Bergen En Henegouwen PM, Verheul HM, Sebestyén Z, Kuball J, Bonvin AM, de Gruijl TD, van der Vliet HJ. de Bruin RC, et al. Among authors: kuball j. J Immunol. 2017 Jan 1;198(1):308-317. doi: 10.4049/jimmunol.1600948. Epub 2016 Nov 28. J Immunol. 2017. PMID: 27895170
γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs.
Gründer C, van Dorp S, Hol S, Drent E, Straetemans T, Heijhuurs S, Scholten K, Scheper W, Sebestyen Z, Martens A, Strong R, Kuball J. Gründer C, et al. Among authors: kuball j. Blood. 2012 Dec 20;120(26):5153-62. doi: 10.1182/blood-2012-05-432427. Epub 2012 Sep 27. Blood. 2012. PMID: 23018643 Free article.
γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia.
Scheper W, van Dorp S, Kersting S, Pietersma F, Lindemans C, Hol S, Heijhuurs S, Sebestyen Z, Gründer C, Marcu-Malina V, Marchant A, Donner C, Plachter B, Vermijlen D, van Baarle D, Kuball J. Scheper W, et al. Among authors: kuball j. Leukemia. 2013 Jun;27(6):1328-38. doi: 10.1038/leu.2012.374. Epub 2013 Jan 1. Leukemia. 2013. PMID: 23277330
Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.
Scheper W, Sebestyen Z, Kuball J. Scheper W, et al. Among authors: kuball j. Front Immunol. 2014 Nov 20;5:601. doi: 10.3389/fimmu.2014.00601. eCollection 2014. Front Immunol. 2014. PMID: 25477886 Free PMC article. Review.
Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer.
Straetemans T, Gründer C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bönig H, Sebestyen Z, Kuball J. Straetemans T, et al. Among authors: kuball j. Clin Cancer Res. 2015 Sep 1;21(17):3957-68. doi: 10.1158/1078-0432.CCR-14-2860. Epub 2015 May 19. Clin Cancer Res. 2015. PMID: 25991821
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T. Drent E, et al. Among authors: kuball j. Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8. Haematologica. 2016. PMID: 26858358 Free PMC article.
RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.
Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau C, van Noorden M, Peigné CM, Olive D, Lebbink RJ, Oostvogels R, Mutis T, Schuurhuis GJ, Adams EJ, Scotet E, Kuball J. Sebestyen Z, et al. Among authors: kuball j. Cell Rep. 2016 May 31;15(9):1973-85. doi: 10.1016/j.celrep.2016.04.081. Epub 2016 May 19. Cell Rep. 2016. PMID: 27210746 Free PMC article.
Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.
de Bruin RCG, Stam AGM, Vangone A, van Bergen En Henegouwen PMP, Verheul HMW, Sebestyén Z, Kuball J, Bonvin AMJJ, de Gruijl TD, van der Vliet HJ. de Bruin RCG, et al. Among authors: kuball j. J Immunol. 2017 May 1;198(9):3759. doi: 10.4049/jimmunol.1700317. J Immunol. 2017. PMID: 28416722 No abstract available.
211 results